Beurskingpin schreef op 19 juli 2017 16:13:
Vertex aim to start Phase III for the triple combination in H1 2018. Vertex have stated that they and the regulators aim to make the trials expedited, to get it to patients quickly. However, given that the trials are planned start in H1 2018, we believe that the compounds are unlikely to be approved during 2018, and a 2019 approval could be more likely. We believe that this makes the two GLPG Phase 2 readouts in 2018 more important. We see a window of opportunity for Galapagos to start Phase 3 trials in 2018, before Vertex's triple combination therapy is approved.
====>> Belangrijk!